Alnylam Pharmaceuticals, Inc. News Releases http://investors.alnylam.com/ Alnylam Pharmaceuticals, Inc. News Releases en Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting http://investors.alnylam.com/news-releases/news-release-details/alnylam-presents-new-onpattror-patisiran-results-2019-peripheral − Patisiran Global Open-Label Extension (OLE) Study Demonstrates Maintained Reversal of Disease Progression and Consistent Safety Profile, with Greater Than Four Years of Patient Experience and Over 6,000 Doses Administered – − APOLLO Patients Previously on Tafamidis Benefited from Patisiran with Mon, 24 Jun 2019 07:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23896 Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-progress-rnai-therapeutics-platform-including −Preclinical Proof of Concept for Oral Delivery Achieved, Demonstrating Robust, Dose-Dependent Silencing of Liver-Expressed Target in Rodents, with Durability Profile Similar to Subcutaneous Administration – − Company Also Reports on New Advances in CNS and Ocular Delivery, Demonstrating Durable Fri, 21 Jun 2019 07:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23891 Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-approval-japan-onpattror-treatment-hereditary − ONPATTRO is the First RNAi Therapeutic Approved in Japan – − Approval Marks the Arrival of an Entirely New Treatment Approach for People Living with hATTR Amyloidosis with Polyneuropathy in Japan – CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Jun. 18, 2019-- Alnylam Pharmaceuticals, Inc. Tue, 18 Jun 2019 08:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23886 Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) http://investors.alnylam.com/news-releases/news-release-details/alnylam-completes-enrollment-illuminate-phase-3-study-lumasiran − On Track to Report ILLUMINATE-A Topline Results in Late 2019 – − In Addition, Company Reports Final Positive Results from Phase 1/2 Study of Lumasiran – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 17, 2019-- Alnylam Pharmaceuticals, Inc.  (Nasdaq:ALNY), the leading RNAi therapeutics company, Mon, 17 Jun 2019 07:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23881 Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN) http://investors.alnylam.com/news-releases/news-release-details/alnylam-report-new-clinical-results-onpattror-patisiran – Data from Ongoing Open-Label Extension Study Highlight Durable Halting or Reversal of Neuropathy Disease Progression Relative to Baseline and Consistent Safety Profile of ONPATTRO in Patients with hATTR Amyloidosis – – Alnylam to Share Data Evaluating Treatment with ONPATTRO in Patients Thu, 13 Jun 2019 08:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23876 Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria http://investors.alnylam.com/news-releases/news-release-details/alnylam-completes-rolling-submission-new-drug-application-us − First Potential Treatment Demonstrating Substantial Reduction in the Frequency of Porphyria Attacks – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of Wed, 05 Jun 2019 07:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23841 Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension http://investors.alnylam.com/news-releases/news-release-details/alnylam-doses-first-patient-phase-1-study-aln-agt − Initial Results Expected in Late 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2019-- Alnylam Pharmaceuticals, Inc.  (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Company’s Phase 1 study of ALN-AGT, an investigational RNAi Fri, 31 May 2019 07:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23836 Alnylam to Webcast Presentations at Upcoming June Investor Conferences http://investors.alnylam.com/news-releases/news-release-details/alnylam-webcast-presentations-upcoming-june-investor-2 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at Thu, 30 May 2019 16:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23831 Alnylam Announces New Leadership Appointments http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-new-leadership-appointments − Company Appoints Chief Human Resources Officer and Chief Scientific Officer – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2019-- Alnylam Pharmaceuticals, Inc.  (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Company’s Senior Vice Wed, 29 May 2019 08:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23816 Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019 http://investors.alnylam.com/news-releases/news-release-details/alnylam-webcast-presentation-bank-america-merrill-lynch-health CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 Thu, 09 May 2019 07:00:00 -0400 Alnylam Pharmaceuticals, Inc. News Releases 23791